A detailed history of Exodus Point Capital Management, LP transactions in Argenx Se stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 13,886 shares of ARGX stock, worth $6.05 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
13,886
Previous 14,281 2.77%
Holding current value
$6.05 Million
Previous $7.02 Million 22.13%
% of portfolio
0.04%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$356.95 - $413.29 $140,995 - $163,249
-395 Reduced 2.77%
13,886 $5.47 Million
Q3 2023

Nov 09, 2023

SELL
$369.35 - $548.43 $3.59 Million - $5.34 Million
-9,731 Reduced 40.53%
14,281 $7.02 Million
Q2 2023

Aug 10, 2023

SELL
$360.14 - $422.58 $2.67 Million - $3.13 Million
-7,417 Reduced 23.6%
24,012 $9.36 Million
Q1 2023

May 11, 2023

BUY
$334.23 - $403.65 $4.68 Million - $5.65 Million
13,996 Added 80.28%
31,429 $11.7 Million
Q4 2022

Feb 13, 2023

BUY
$342.17 - $402.31 $2.3 Million - $2.7 Million
6,712 Added 62.61%
17,433 $6.6 Million
Q3 2022

Nov 10, 2022

SELL
$343.2 - $395.75 $2.28 Million - $2.62 Million
-6,630 Reduced 38.21%
10,721 $3.79 Million
Q2 2022

Aug 19, 2022

BUY
$269.58 - $378.88 $4.68 Million - $6.57 Million
17,351 New
17,351 $6.57 Million
Q2 2021

Aug 16, 2021

SELL
$257.11 - $319.92 $508,820 - $633,121
-1,979 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$268.3 - $380.31 $530,965 - $752,633
1,979 New
1,979 $545,000
Q3 2020

Nov 16, 2020

SELL
$215.51 - $272.51 $3.92 Million - $4.96 Million
-18,205 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$127.44 - $232.72 $2.32 Million - $4.24 Million
18,205 New
18,205 $4.1 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $24.1B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.